Pathology Department, Stanford University, 300 Pasteur Drive Room H-1402, M/C 5626 Stanford, CA 94305, USA.
Anesth Analg. 2013 Jan;116(1):15-34. doi: 10.1213/ANE.0b013e318273f4ae. Epub 2012 Dec 7.
Patient blood management(1,2) incorporates patient-centered, evidence-based medical and surgical approaches to improve patient outcomes by relying on the patient's own (autologous) blood rather than allogeneic blood. Particular attention is paid to preemptive measures such as anemia management. The emphasis on the approaches being "patient-centered" is to distinguish them from previous approaches in transfusion medicine, which have been "product-centered" and focused on blood risks, costs, and inventory concerns rather than on patient outcomes. Patient blood management(3) structures its goals by avoiding blood transfusion(4) with effective use of alternatives to allogeneic blood transfusion.(5) These alternatives include autologous blood procurement, preoperative autologous blood donation, acute normovolemic hemodilution, and intra/postoperative red blood cell (RBC) salvage and reinfusion. Reviewed here are the available pharmacologic tools for anemia and blood management: erythropoiesis-stimulating agents (ESAs), iron therapy, hemostatic agents, and potentially, artificial oxygen carriers.
患者血液管理(1,2)包含以患者为中心的、基于证据的医学和外科方法,通过依靠患者自身(自体)血液而不是异体血液来改善患者的预后。特别关注如贫血管理等预防措施。强调方法“以患者为中心”是为了将其与输血医学中的以前的方法区分开来,后者一直“以产品为中心”,侧重于血液风险、成本和库存问题,而不是患者的预后。患者血液管理(3)通过有效利用异体输血(4)的替代方法来避免输血(5),来构建其目标。这些替代方法包括自体血液采集、术前自体献血、急性等容血液稀释以及围手术期红细胞(RBC)回收和再输注。本文回顾了用于贫血和血液管理的现有药物工具:红细胞生成刺激剂(ESA)、铁剂、止血剂,以及潜在的人工氧载体。